Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  therapeutic autologous dendritic cells
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 49 for your search:
Start Over
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2015045010, NCT02415699
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: 020221, NCT00045968
Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GMPE, NCT01256801
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CL-CA-P01, 2015-001984-38, NCT01875653
The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: pepDCIL2- HMO-CTIL, NCT00279058
Vaccine Therapy in Treating Patients With Ductal Carcinoma In Situ of the Breast
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000644921, UPCC-15107, 807010, NCT00923143
Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: NL22553.000.08, KUN2008-035, NCT00929019
DC Vaccination for Postremission Therapy in AML
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2010-022446-24, NCT01734304
Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: S1+DC CIK-P, NCT01781520
Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: S1+DC CIK- G, NCT01783951
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: NWBio 050012, NCT01882946
Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MC-01-2013, NCT01883518
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 307-CTC-DC/CIK, NCT01898663
Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 8 to 61
Sponsor: Other
Protocol IDs: 307-CTC-DC/CIK-Leukemia, NCT01956630
Consolidation Therapy for Metastatic Solid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Kirovax 002, NCT02223312
Treatment of Patients With Progressive and/or Refractory Solid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Kirovax 003, NCT02224599
Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 13-038, NCT02248402
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 2 to 21
Sponsor: Other
Protocol IDs: 14.0855, NCT02332889
DC Vaccination for Post-remission Therapy in AML
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CD-FDC-001, NCT02405338
Safety and Efficiency of ?d T Cell Against Breast Cancer(Her-, er-, and pr-)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Gd T cell, NCT02418481
Safety and Efficiency of ?d T Cell Against Hepatocellular Liver Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Gd T cell and Hepatocellular, NCT02425735
Safety and Efficiency of ?d T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Gd T cell and lung cancer, NCT02425748
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 11-128, 5P01CA132714, NCT02432378
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: CDR0000369699, DFCI-03123, NCT00085397
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MMH-I-S-321, MMH-I-S-401, NCT00521287
Start Over